A broad spectrum antibiotic that could become the first of its kind to treat specific Gram negative and Gram positive infections as well as tularemia, a bioterrorism threat, will undergo the last steps in development with support from the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).
Under an 18-month, $20 million agreement between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Swiss drugmaker Basilea Pharmaceutica (SIX: BSLN), the company will conduct Phase III clinical studies of the antibiotic, ceftobiprole, in treating specific Gram-negative and Gram-positive infections.
Accord could be extended to a total of up to around $100 million
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze